Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 4 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Revolution Medicines Inc. has 11 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are reviewed by 10 distinct examiners, which indicates a high level of individual variety in the examination process. However, these examiners are concentrated within only 4 distinct art units, suggesting that the company's pharmaceutical research is focused on a few specific technical categories. This concentration within a small number of art units may lead to more consistent application of departmental policies, even with 10 different examiners involved.
The busiest examiner, CHANDRAKUMAR, NIZAL S, is responsible for 2 pending office actions. Although there are 10 distinct examiners, the concentration within 4 distinct art units means that many examiners likely share similar departmental guidelines. With 11 pending actions in total, the prosecution strategy must balance the specific preferences of 10 different individuals while navigating the broader standards of a small number of art units. Practitioners should look for trends across the 4 distinct art units to help predict how the 10 distinct examiners might react to various legal and technical arguments, as the administrative overlap provides a common ground for the 11 pending actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (36%) |
| §112 only | 2 (18%) |
| Double-patenting only | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.2% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18769009 | RAS INHIBITORS | KIM, SEONG JONG | — |
| 18720331 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | WELLS, LAUREN QUINLAN | — |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | CHANDRAKUMAR, NIZAL S | 132d overdue |
| 19308717 | RAS INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | CHANDRAKUMAR, NIZAL S | — |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18720331 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | WELLS, LAUREN QUINLAN | — |
| 18591721 | RAS INHIBITORS | MCDOWELL, BRIAN E | — |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 4 |
| 1625 | 3 |
| 1621 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19308717 | RAS INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Non-Final OA | — | Pending | Aug 25, 2025 |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | CHANDRAKUMAR, NIZAL S | 1625 | §103Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §102§112Other | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18769009 | RAS INHIBITORS | KIM, SEONG JONG | 1621 | §112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18720331 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | WELLS, LAUREN QUINLAN | — | §102§103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18634246 | SYNTHESIS OF RAS INHIBITORS | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18591721 | RAS INHIBITORS | MCDOWELL, BRIAN E | 1624 | §112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18559932 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | BAUER, NICOLA MARIA | 1621 | §103§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | 1622 | §102§112 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 132d overdue | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRevolution Medicines Inc. has 11 pending office actions as of October 2026, spread across 4 art units and 10 examiners.
Nizal S Chandrakumar has the most, with 2 of Revolution Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
